-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the price of Envolimab injection (Envida®) jointly developed by Sidi Di Pharmaceutical, Corning Jereh Pharmaceuticals and Simcere Pharmaceuticals has been announced, with a unit price of RMB 5980 per bottle
Envolimab is a monospecific antibody composed of a single domain antibody (sdAb) and an Fc segment.
On November 25, the State Food and Drug Administration approved the listing of PD-L1 antibody envolimab for subcutaneous injection, becoming the world’s first approved PD-(L)1 antibody for subcutaneous injection.
Envolimab was approved in China based on the data of a single-arm, open-label Phase 2 key clinical trial.
Prior to this, Gale and Corning Jerry reached an exclusive global development agreement for envolimab (ASC22, also known as KN035) for the treatment of all viral diseases, including hepatitis B, outside of Greater China
It is worth mentioning that the PD-1 products of Junshi Bio, Cinda Bio, BeiGene, and Hengrui Medicine have entered the 2021 National Medical Insurance Catalog, and the price is about 3.
Reference source: Yaorongyun, Wuxi AppTec
